Febrile, Allergic, and Nonimmune Transfusion Reactions

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 826-846

  Pomper, Gregory J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991475897     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch53     Document Type: Chapter

References (130)

1. Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: Good prophylaxis or bad practice? Transfus Med Rev 2007;21:1-12.
2. Chambers LA, Kruskall MS, Pacini DG, Donovan LM. Febrile reactions after platelet transfusion: The effect of single versus multiple donors. Transfusion 1990;30:219-21.
3. Mangano MM, Chambers LA, Kruskall MS. Limited efficacy of leu- kopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol 1991;95:733-8.
4. Muylle L, Wouters E, De Bock R, Peetermans ME. Reactions to platelet transfusion: The effect of the storage time of the concentrate. Transfus Med 1992;2:289-93.
5. Heddle NM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993;33:794-7.
6. Kelley DL, Mangini J, Lopez-Plaza I, Triulzi DJ. The utility of <3- day-old whole-blood platelets in reducing the incidence of febrile nonhemolytic transfusion reactions. Transfusion 2000;40:439-42.
7. Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999;6:420-6.
8. Stack G, Berkowicz D. Cytokine production during blood component storage. In: Davenport RD, Snyder EL, eds. Cytokines in transfusion medicine: A primer. Bethesda, MD: AABB Press, 1997:21-59.
9. Addas-Carvalho M, Salles TS, Saad ST. The association of cytokine gene polymorphisms with febrile non-hemolytic transfusion reaction in multitransfused patients. Transfus Med 2006;16:184-91.
10. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: Some concepts have changed. J Endotoxin Res 2004;10:201-22.
11. Blatteis CM. The onset of fever: New insights into its mechanism. Prog Brain Res 2007;162:3-14.
12. Romanovsky AA, Almeida MC, Aronoff DM, et al. Fever and hypothermia in systemic inflammation: Recent discoveries and revisions. Front Biosci 2005;10:2193-216.
13. Lazarus M, Yoshida K, Coppari R, et al. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci 2007;10:1131-3.
14. Vo TD, Cowles J, Heal JM, Blumberg N. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions. Transfus Med 2001;11:45-7.
15. de Rie MA, van der Plas-van Dalen CM, Engelfriet CP, dem Borne AE. The serology of febrile transfusion reactions. Vox Sang 1985;49:126-34.
16. Payne R. The association of febrile transfusion reactions with leuko- agglutinins. Vox Sang 1957;2:233-41.
17. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992;117:151-62.
18. Perkins HA, Payne R, Ferguson J, Wood M. Nonhemolytic febrile transfusion reactions. Quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes. Vox Sang 1966;11:578-600.
19. Paglino JC, Pomper GJ, Fisch GS, et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004;44:16-24.
20. Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001;41:997-1000.
21. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
22. Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999;39:231-8.
23. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994;34:20-5.
24. Hetland G, Mollnes TE, Bergh K, et al. Effect of filtration and storage of platelet concentrates on the production of the chemotaxins C5a, interleukin 8, tumor necrosis factor alpha, and leukotriene B4. Transfusion 1998;38:16-23.
25. Silliman CC. Transfusion-related acute lung injury. Transfus Med Rev 1999;13:177-86.
26. Blumberg N, Gettings KF, Turner C, et al. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006;46:1813-21.
27. Wakamoto S, Fujihara M, Kuzuma K, et al. Biologic activity of RANTES in apheresis PLT concentrates and its involvement in nonhemolytic transfusion reactions. Transfusion 2003;43:1038-46.
28. Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006;46:800-10.
29. Stack G, Baril L, Napychank P, Snyder EL. Cytokine generation in stored, white cell-reduced, and bacterially contaminated units of red cells. Transfusion 1995;35:199-203.
30. ElKattan I, Anderson J, Yun JK, et al. Correlation of cytokine elaboration with mononuclear cell adhesion to platelet storage bag plastic polymers: A pilot study. Clin Diagn Lab Immunol 1999;6:509-13.
31. Palavecino EL, Yomtovian RA, Jacobs MR. Detecting bacterial contamination in platelet products. Clin Lab 2006;52:443-56.
32. Sharma AD, Grocott HP. Platelet transfusion reactions: febrile nonhemolytic reaction or bacterial contamination? Diagnosis, detection, and current preventive modalities. J Cardiothorac Vasc Anesth 2000;14:460-6.
33. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
34. Latta KS, Ginsberg B, Barkin RL. Meperidine: A critical review. Am J Ther 2002;9:53-68.
35. Oberman HA. Controversies in transfusion medicine: Should a febrile transfusion response occasion the return of the blood component to the blood bank? Con. Transfusion 1994;34:353-5.
36. Tobian AA, King KE, Ness PM. Transfusion premedications: A growing practice not based on evidence. Transfusion 2007;47:1089-96.
37. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994;84:1703-21.
38. Hughes A, Mijovic V, Brozovic B, Davies TD. Leucocyte-depleted blood: A comparison of cell-washing techniques. Vox Sang 1982;42:145-50.
39. Goldfinger D, Lowe C. Prevention of adverse reactions to blood transfusion by the administration of saline-washed red blood cells. Transfusion 1981;21:277-80.
40. Swank RL, Seaman GV. Microfiltration and microemboli: A history. Transfusion 2000;40:114-19.
41. Schned AR, Silver H. The use of microaggregate filtration in the prevention of febrile transfusion reactions. Transfusion 1981;21:675-81.
42. Wenz B. Microaggregate blood filtration and the febrile transfusion reaction. A comparative study. Transfusion 1983;23:95-8.
43. Parravicini A, Rebulla P, Apuzzo J, et al. The preparation of leukocyte-poor red cells for transfusion by a simple cost-effective technique. Transfusion 1984;24:508-9.
44. Dzik S. Leukodepletion blood filters: Filter design and mechanisms of leukocyte removal. Transfus Med Rev 1993;7:65-77.
45. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004;44:25-9.
46. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: What blood component should be given next? Vox Sang 1982;42:318-21.
47. Domen RE, Hoeltge GA. Allergic transfusion reactions: An evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003;127:316-20.
48. Muylle L, Beert JF, Mertens G, Bult H. Histamine synthesis by white cells during storage of platelet concentrates. Vox Sang 1998;74:193-7.
49. Nielsen HJ, Edvardsen L, Vangsgaard K, et al. Time-dependent histamine release from stored human blood products. Br J Surg 1996;83:259-62.
50. Frewin DB, Jonsson JR, Frewin CR, et al. Influence of blood storage time and plasma histamine levels on the pattern of transfusion reactions. Vox Sang 1989;56:243-6.
51. Kluter H, Bubel S, Kirchner H, Wilhelm D. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999;39:1179-84.
52. Ring J, Behrendt H. H1- and H2-antagonists in allergic and pseudoallergic diseases. Clin Exp Allergy 1990;20(Suppl 2):43-9.
53. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000;36:462-8.
54. Kennedy LD, Cruz JM, Restino MS. Comparison of acetaminophen and diphenhydramine versus placebo for the prevention of febrile or allergic transfusion-associated reactions (abstract). Blood 1999;94:375a.
55. Wang SE, Lara PN Jr. , Lee-Ow A, et al. Acetaminophen and diphenhydramine as premedication for platelet transfusions: A prospective randomized double-blind placebo-controlled trial. Am J Hematol 2002;70:191-4.
56. Buck SA, Kickler TS, McGuire M, et al. The utility of platelet washing using an automated procedure for severe platelet allergic reactions. Transfusion 1987;27:391-3.
57. Blumberg N, Heal JM, Rowe JM. A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia. BMC Blood Disord 2004;4:6.
58. Sandler SG. How I manage patients suspected of having had an IgA anaphylactic transfusion reaction. Transfusion 2006;46:10-13.
59. Abramson J, Pecht I. Regulation of the mast cell response to the type 1 Fc epsilon receptor. Immunol Rev 2007;217:231-54.
60. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: Current and future approaches. J Allergy Clin Immunol 2007;120(Suppl):S2-24.
61. Cauwels A, Janssen B, Buys E, et al. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest 2006;116:2244-51.
62. Shimode N, Yasuoka H, Kinoshita M, et al. Severe anaphylaxis after albumin infusion in a patient with ahaptoglobinemia. Anesthesiology 2006;105:425-6.
63. Gilstad CW. Anaphylactic transfusion reactions. Curr Opin Hematol 2003;10:419-23.
64. Lieberman P, Kemp SF, Oppenheimer J, et al. The diagnosis and management of anaphylaxis: An updated practice parameter. J Allergy Clin Immunol 2005;115(Suppl):S483-523.
65. Holcomb JB. Damage control resuscitation. J Trauma 2007;62 (Suppl):S36-7.
66. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma 2006;60(Suppl):S91-6.
67. Johansson PI, Stensballe J, Rosenberg I, et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: Evaluating a change in transfusion practice. Transfusion 2007;47:593-8.
68. Perkins RM, Aboudara MC, Abbott KC, Holcomb JB. Resuscitative hyperkalemia in noncrush trauma: A prospective, observational study. Clin J Am Soc Nephrol 2007;2:313-19.
69. Spinella PC, Perkins JG, Grathwohl KW, et al. Risks associated with fresh whole blood and red blood cell transfusions in a combat support hospital. Crit Care Med 2007;35:2576-81.
70. Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev 1988;2:76-94.
71. Bolan CD, Wesley RA, Yau YY, et al. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003;43:1403-13.
72. Bolan CD, Cecco SA, Wesley RA, et al. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002;42:935-46.
73. Bolan CD, Cecco SA, Yau YY, et al. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 2003;43:1414-22.
74. Diaz J, Acosta F, Parrilla P, et al. Citrate intoxication and blood concentration of ionized calcium in liver transplantation. Transplant Proc 1994;26:3669-70.
75. Jawan B, de Villa V, Luk HN, et al. Ionized calcium changes during living-donor liver transplantation in patients with and without administration of blood-bank products. Transpl Int 2003;16:510-14.
76. Haddad S, Leitman SF, Wesley RA, et al. Placebo-controlled study of intravenous magnesium supplementation during large-volume leu- kapheresis in healthy allogeneic donors. Transfusion 2005;45:934-44.
77. Hester JP, Ayyar R. Anticoagulation and electrolytes. J Clin Apher 1984;2:41-51.
78. Korbling M, Huh YO, Durett A, et al. Allogeneic blood stem cell transplantation: Peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft- versus-host disease. Blood 1995;86:2842-8.
79. Ronquillo J, Yau Y, Stevens W, et al. Acute and sub-acute citrate mediated effects and responses to IV calcium in healthy apheresis donors (abstract). Transfusion 2007;47(Suppl):14A.
80. Latham JT, Jr. , Bove JR, Weirich FL. Chemical and hematologic changes in stored CPDA-1 blood. Transfusion 1982;22:158-9.
81. Carvalho B, Quiney NF. 'Near-miss' hyperkalaemic cardiac arrest associated with rapid blood transfusion. Anaesthesia 1999;54:1094-6.
82. Woodforth IJ. Resuscitation from transfusion-associated hyperkalaemic ventricular fibrillation. Anaesth Intens Care 2007;35:110-13.
83. Bansal I, Calhoun BW, Joseph C, et al. A comparative study of reducing the extracellular potassium concentration in red blood cells by washing and by reduction of additive solution. Transfusion 2007;47:248-50.
84. Swindell CG, Barker TA, McGuirk SP, et al. Washing of irradiated red blood cells prevents hyperkalaemia during cardiopulmonary bypass in neonates and infants undergoing surgery for complex congenital heart disease. Eur J Cardiothorac Surg 2007;31:659-64.
85. Liu EA, Mannino FL, Lane TA. Prospective, randomized trial of the safety and efficacy of a limited donor exposure transfusion program for premature neonates. J Pediatr 1994;125:92-6.
86. Buchholz DH, Borgia JF, Ward M, et al. Comparison of Adsol and CPDA-1 blood preservatives during simulated massive resuscitation after hemorrhage in swine. Transfusion 1999;39:998-1004.
87. Boyan CP, Howland WS. Blood temperature: A critical factor in massive transfusion. Anesthesiology 1961;22:559-63.
88. Hrovat TM, Passwater M, Palmer RN for the Scientific Section Coordinating Committee. Guidelines for the use of blood warming devices. Bethesda, MD: AABB, 2002.
89. Dubick MA, Brooks DE, Macaitis JM, et al. Evaluation of commercially available fluid-warming devices for use in forward surgical and combat areas. Mil Med 2005;170:76-82.
90. Cohn SM, Stack GE. In vitro comparison of heated saline-blood admixture with a heat exchanger for rapid warming of red blood cells. J Trauma 1993;35:688-90.
91. Snyder EL, Bookbinder M. Role of microaggregate blood filtration in clinical medicine. Transfusion 1983;23:460-70.
92. Rentas FJ, Macdonald VW, Rothwell SW, et al. White particulate matter found in blood collection bags consist of platelets and leukocytes. Transfusion 2004;44:959-66.
93. Collins JA, James PM, Bredenberg CE, et al. The relationship between transfusion and hypoxemia in combat casualties. Ann Surg 1978;188:513-20.
94. Westphal-Varghese B, Erren M, Westphal M, et al. Processing of stored packed red blood cells using autotransfusion devices decreases potassium and microaggregates: A prospective, randomized, single-blinded in vitro study. Transfus Med 2007;17:89-95.
95. Fiebig EW, Wu AH, Krombach J, et al. Transfusion-related acute lung injury and transfusion-associated circulatory overload: Mutually exclusive or coexisting entities? Transfusion 2007;47:171-2.
96. Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriu- retic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005;45:1056-63.
97. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007;14:682-7.
98. Rana R, Fernandez-Perez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: A retrospective study. Transfusion 2006;46:1478-83.
99. Marriott HLKA. Volume and rate in blood transfusion for the relief of anaemia. Br Med J 1940;1:1043-6.
100. Sasidharan P, Heimler R. Alterations in pulmonary mechanics after transfusion in anemic preterm infants. Crit Care Med 1990;18:1360-2.
101. Nelle M, Hoecker C, Linderkamp O. Effects of red cell transfusion on pulmonary blood flow and right ventricular systolic time intervals in neonates. Eur J Pediatr 1997;156:553-6.
102. Cyr M, Eastlund T, Blais C Jr. , et al. Bradykinin metabolism and hypotensive transfusion reactions. Transfusion 2001;41:136-50.
103. Michon B, Moghrabi A, Winikoff R, et al. Complications of apher- esis in children. Transfusion 2007;47:1837-42.
104. Weinstein R. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apher 1996;11:204-10.
105. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994;34:891-4.
106. Adverse ocular reactions following transfusions-United States, 1997-1998. MMWR Morb Mortal Wkly Rep 1998;47:49-50.
107. Alonso-Echanove J, Sippy BD, Chin AE, et al. Nationwide outbreak of red eye syndrome associated with transfusion of leukocyte-reduced red blood cell units. Infect Control Hosp Epidemiol 2006;27:1146-52.
108. Rock G, Secours VE, Franklin CA, et al. The accumulation of mono-2-ethylhexylphthalate (MEHP) during storage of whole blood and plasma. Transfusion 1978;18:553-8.
109. Kluwe WM, Haseman JK, Huff JE. The carcinogenicity of di(2- ethylhexyl) phthalate (DEHP) in perspective. J Toxicol Environ Health 1983;12:159-69.
110. Salkie ML, Hannon JL. Anti-plasticizer specific IgE is present in the serum of transfused patients. Clin Invest Med 1995;18:419-23.
111. Rock G, Tocchi M, Ganz PR, Tackaberry ES. Incorporation of plasticizer into red cells during storage. Transfusion 1984;24:493-8.
112. Labow RS, Tocchi M, Rock G. Platelet storage. Effects of leachable materials on morphology and function. Transfusion 1986;26:351-7.
113. Jaeger RJ, Rubin RJ. Plasticizers from plastic devices extraction, metabolism, and accumulation by biological systems. Science 1970;170:460-2.
114. Snyder EL, Hedberg SL, Napychank PA, et al. Stability of red cell antigens and plasma coagulation factors stored in a non-diethyl- hexyl phthalate-plasticized container. Transfusion 1993;33:515-19.
115. Latini G, Del Vecchio A, Massaro M, et al. In utero exposure to phthalates and fetal development. Curr Med Chem 2006;13:2527-34.
116. Burkhart HM, Joyner N, Niles S, et al. Presence of plasticizer di-2(ethylhexyl)phthalate in primed extracorporeal circulation circuits. ASAIO J 2007;53:365-7.
117. Ito Y, Yamanoshita O, Asaeda N, et al. Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome prolifera- tor-activated receptor alpha-independent pathway. J Occup Health 2007;49:172-82.
118. Brobyn RD. The human toxicology of dimethyl sulfoxide 45. Ann N Y Acad Sci 1975;243:497-506.
119. Jacob SW, Wood DC. Dimethyl sulfoxide (DMSO). Toxicology, pharmacology, and clinical experience. Am J Surg 1967;114:414-26.
120. Davis JM. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990;75:781-6.
121. Kessinger A, Schmit-Pokorny K, Smith D, Armitage J. Cryopreservation and infusion of autologous peripheral blood stem cells. Bone Marrow Transplant 1990;5(Suppl 1):25-7.
122. Zambelli A. Clinical toxicity of cryopreserved circulating progenitor cells infusion 1. Anticancer Res 1998;18:4705-8.
123. Lopez-Jimenez J. Cardiovascular toxicities related to the infusion of cryopreserved grafts: Results of a controlled study. Bone Marrow Transplant 1994;13:789-93.
124. Keung YK. Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transplant 1994;14:363-7.
125. Rowley SD. Effect of DMSO exposure without cryopreserva- tion on hematopoietic progenitor cells. Bone Marrow Transplant 1993;11:389-93.
126. Klein HG, Strauss RG, Schiffer CA. Granulocyte transfusion therapy. Semin Hematol 1996;33:359-68.
127. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000;95:3302-9.
128. Meyer-Koenig U, Hufert FT, Duffner U, et al. G-CSF-mobilised granulocyte transfusion to an ALL patient complicated by cytomegalovirus transmission. Bone Marrow Transplant 2004;34:1095-6.
129. Domen RE. Adverse reactions associated with autologous blood transfusion: Evaluation and incidence at a large academic hospital. Transfusion 1998;38:296-300.
130. Benavides S, Nicol K, Koranyi K, Nahata MC. Yersinia septic shock following an autologous transfusion in a pediatric patient. Transfus Apher Sci 2003;28:19-23.